Status:
COMPLETED
Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Hyperglucagonemia
Eligibility:
MALE
18-70 years
Phase:
NA
Brief Summary
The aim of the study was to investigate the role of the Trasylol in glucagon prevention in degradation using radioimmunoactive method with I125. Additionally different incubation time was introduced i...
Eligibility Criteria
Inclusion
- Caucasians 18 years or older with Type 2 diabetes (WHO criteria)
Exclusion
- HbA1c \>9 %
- Liver disease (ALAT/ASAT \>2 x upper normal limit)
- Diabetic nephropathy (s-creatinine \>130 µM or albuminuria)
- Proliferative diabetic retinopathy (anamnestic)
- Severe arteriosclerosis or heart failure (NYHA group III og IV)
- Anemia
- treatment with medication not applicable to pause for 12 hours
- pregnancy or lactation
- Fasting plasma glucose \>15 mM on screening day.
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01436734
Start Date
July 1 2011
End Date
May 1 2013
Last Update
July 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gentofte Hospital
Hellerup, Denmark, 2900